These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22532636)

  • 61. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).
    Augustsson J; Neovius M; Cullinane-Carli C; Eksborg S; van Vollenhoven RF
    Ann Rheum Dis; 2010 Jan; 69(1):126-31. PubMed ID: 19470527
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.
    Levitsky A; Forslind K; van Vollenhoven RF;
    Scand J Rheumatol; 2015; 44(5):348-53. PubMed ID: 25992914
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
    Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
    Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab.
    Klarenbeek NB; Güler-Yüksel M; van der Heijde DM; Hulsmans HM; Kerstens PJ; Molenaar TH; de Sonnaville PB; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2010 Dec; 69(12):2107-13. PubMed ID: 20610442
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.
    Glintborg B; Østergaard M; Krogh NS; Tarp U; Manilo N; Loft AG; Hansen A; Schlemmer A; Fana V; Lindegaard HM; Nordin H; Rasmussen C; Ejstrup L; Jensen DV; Petersen PM; Hetland ML
    Ann Rheum Dis; 2013 Jul; 72(7):1149-55. PubMed ID: 22941767
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
    Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.
    Rantalaiho V; Kautiainen H; Järvenpää S; Korpela M; Malmi T; Hannonen P; Kaipiainen-Seppänen O; Yli-Kerttula T; Möttönen T; Mustila A; Karjalainen A; Paimela L; Uutela T; Leirisalo-Repo M;
    J Rheumatol; 2014 Dec; 41(12):2379-85. PubMed ID: 25274892
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
    Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
    Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.
    Hirata S; Li W; Kubo S; Fukuyo S; Mizuno Y; Hanami K; Sawamukai N; Yamaoka K; Saito K; Defranoux NA; Tanaka Y
    Mod Rheumatol; 2016 Nov; 26(6):850-856. PubMed ID: 26873570
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab.
    Vuolteenaho K; Tuure L; Nieminen R; Laasonen L; Leirisalo-Repo M; Moilanen E;
    Scand J Rheumatol; 2022 May; 51(3):180-185. PubMed ID: 34263700
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.
    Saevarsdottir S; Rezaei H; Geborek P; Petersson I; Ernestam S; Albertsson K; Forslind K; van Vollenhoven RF;
    Ann Rheum Dis; 2015 Aug; 74(8):1509-14. PubMed ID: 24706006
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study.
    Ometto F; Raffeiner B; Bernardi L; Bostsios C; Veronese N; Punzi L; Doria A
    Arthritis Res Ther; 2016 Apr; 18():89. PubMed ID: 27080123
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study.
    Benbouazza K; Benchekroun B; Rkain H; Amine B; Bzami F; Benbrahim L; Atouf O; Essakalli M; Abouqal R; Dougados M; Hajjaj-Hassouni N
    BMC Musculoskelet Disord; 2011 Nov; 12():266. PubMed ID: 22111841
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study.
    Hafström I; Engvall IL; Rönnelid J; Boonen A; van der Heijde D; Svensson B;
    BMJ Open; 2014 Jul; 4(7):e005246. PubMed ID: 25079933
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible.
    Kvien TK; Uhlig T; Kristiansen IS
    Drugs; 2001; 61(12):1711-20. PubMed ID: 11693461
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis.
    Weng HH; Ranganath VK; Khanna D; Oh M; Furst DE; Park GS; Elashoff DA; Sharp JT; Gold RH; Peter JB; Paulus HE;
    J Rheumatol; 2010 Mar; 37(3):550-7. PubMed ID: 20110517
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
    Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
    Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Radiographic changes and factors associated with subsequent progression of damage in weight-bearing joints of patients with rheumatoid arthritis under TNF-blocking therapies-three-year observational study.
    Matsushita I; Motomura H; Seki E; Kimura T
    Mod Rheumatol; 2017 Jul; 27(4):570-575. PubMed ID: 27589926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.